Tamarind Hill

At Menlo Ventures, we go ALL IN. This isn’t just a motto, but how we show up everyday for the companies we back, the investors who back us, and each other. When we win, we win as a team. 47 Years 80+ Public Companies 165 + Mergers + Aquisitions $5B+ Under Management We focus on the "three stages of early" We are investors and company builders - we know what it takes to turn a budding idea into a scalable business. We work with early-stage founders to find product-market fit, develop go-to-market strategies, scale their organizations, and support them as they grow. Inception: Our Menlo Labs team helps founders validate early-stage ideas, de-risk opportunities, and build successful foundations. Venture: Our venture team provides series A and B startups with guidance and hands-on help as they build their teams and products. Inflection: Our inflection team supports early growth-stage startups during critical points as they prepare to scale. Our focus areas At every stage from inception through IPO, we invest in game-changing ideas that reinvent life and work. Although we remain open to new ventures within consumer, enterprise, and healthcare, we go deep in the following seven focus areas: AI: Generative AI is breaking into every software vertical, and winners in these markets will create massive economic and societal value. Menlo Ventures is placing bets on the most promising GenAI companies at the infrastructure and application layers, where we see immense potential for groundbreaking businesses that will reshape industries and push the boundaries of what we can achieve. Bio + Healthcare: Innovations at the intersection of advancements in technology and biology will drive major improvements in the quality of our health and the cost of healthcare. At Menlo, we invest at that intersection - backing breakthrough digital health companies (vertical SaaS and digital care) and novel life sciences companies (therapeutic platforms and transformative technologies). Consumer: The world we live in today is enhanced by technologies we might not have thought possible even 10 years ago. There is so much still to come. At Menlo, we invest in the game-changing companies of the future, those that will help us do things better, faster, or cheaper than we can today. Cloud Infrastructure: As enterprises continue migrating to the public cloud, a new generation of companies will write the playbook for the underlying infrastructure that powers their applications. These tools and platforms are built for and cater to the developer, optimized for time-to-integration with beautiful, easy-to-use UIs and APIs. Cybersecurity: In a complex, post-pandemic world, rapid cloud adoption and the proliferation of open-source software have dramatically expanded the attack surface for bad actors against enterprises, governments, and their applications. Additionally, the shift-left approach to software development requires developers to embrace a security-first mindset. As the cyber war continues, Menlo will back the best teams fighting on the frontlines. Fintech: Financial transactions and services power the global economy. Menlo invests in four fintech categories: dev-focused infrastructure and embedded finance (API layers), vertical banking, end-to-end financial services for consumers and SMBs, and tools that serve finance teams and the office of the CFO. SaaS: The shift to the cloud introduced an entirely new business model–Software-as-a-Service–and created unprecedented opportunities for enterprise software companies. Menlo divides the SaaS landscape into three categories, each with a distinct point of view that guides our investment, research, and resources: Departmental SaaS, Vertical SaaS, and Horizontal SaaS. Supply Chain + Automation: This once-in-a-generation reinvention/reinvigoration of the supply chain will create a world that is more efficient, resilient, and sustainable because of the operational efficiencies we gain. With an eye on a more functional future, Menlo invests in a broad range of technologies–robotics and industrial automation among them.

We invest in early-stage, scalable ventures with exceptional founders. We focus on discovering early-stage, tech-enabled startups with significant growth potential in key industries that are reflective of our region and network, with a bias to those in Wisconsin and the Midwest. Investment VerticalsSPORTS, MEDIA & ENTERTAINMENT DIGITAL HEALTH AGRICULTURE, WATER & ENVIRONMENT MANUFACTURING & CONSTRUCTION SUPPLY CHAIN & LOGISTICS CROSS-INDUSTRY TECHNOLOGY Investment CriteriaSTAGE: We invest in early-stage companies that range from pre-revenue to Series A. INDUSTRY: We focus on digitally transforming industries core to the strengths of our partners and region. CHECK SIZE: Our initial check size ranges from $200K to $2M. We are happy to lead deals or co-invest. GEOGRAPHY: We have a bias toward founders based in or connected to Wisconsin and the Midwest. We exclusively invest in the U.S. and Canada. NETWORK: We invest in opportunities where we can add value with our networks and partnerships.

Pureland Global Venture is a direct investment fund and part of the Pureland Group which targets impact investment deals in the medical technology sector. We are Singapore-based with a focus in APAC, India and the US. The fund deals with early-stage companies who have potential to inject value into the patient care system, save lives and reduce gaps in the supply and demand chains. Since we were established, we have invested in multiple medical sectors in both medical devices and ML-based solutions. MISSION - WHAT WE WANT TO ACHIEVE Established with the goal of giving people access to healthcare and also providing them with clinical choices, our mission is to bring medical solutions and savings to 100 million people around the world. We strongly believe in people who don’t just care about profit and who want to make the world a better place by solving real issues and pushing forward the latest evolution in medical technology. We envision bringing together impactful start-ups, commercial partners, insightful advisors and clinical providers in order to build a sustainable foundation for affordable, accessible and high-quality healthcare. WHY HEALTHCARE? Worldwide healthcare spending is expected to continue to rise at an alarming rate with a slight difference in some countries. Of all the leading factors, life expectancy appears to still be on the rise. By 2050, 1/6 people in the world will be over the age of 65 (16%), an increase from 1/11 in 2019 (9%). The number of people aged over 80 is projected to be 426 million by 2050 according to the United Nations population prospects. As we are entering a smart-health generation, the ecosystem demands more cost-effective solutions and appropriate treatments which can be delivered at the appropriate time and location. Clinicians use technology to give more holistic solutions to an aging population and provide more accurate diagnostics. Care delivery stakeholders use data and communicate more effectively and efficiently. Patients are involved in their own treatment plans and more healthcare access is delivered to people who did not previously have access. Unfortunately, we still face issues such as the increasing cost of healthcare, aging population, limited resources and shortages of healthcare professionals in various parts of the world. In order to combat these problems, government support and spending alone is not enough. We believe that these shortages can be filled by technology, which can be our solution for ensuring sufficient healthcare for future generations. This is also the reason why we are keen on enterprises which can provide solutions to combat these issues and create positive changes in the smart-health era. Founded in Singapore, we hope to be able to leverage the geographical advantage of Asia, and put together growth opportunities for these technologies which will make them accessible globally in the long term. WE SUPPORT START-UPS POST INVESTMENTFOUNDER SUPPORT: Start-ups regularly face critical decision-making as businesses grow from continuous market feedback and unexpected situations. We understand how difficult it can be and we will work together with the founders as a team in order to assist them with scaling their company, whether from networking referrals at the R&D stage, business strategy improvement at the growth stage, or EBITDA optimisation at a later stage. We offer support to founders for the optimisation of team structure as their businesses grow so they can overcome challenges and compete globally. MANUFACTURING SUPPORT: Manufacturing is one of the most crucial aspects of any device company, but it is often where mistakes are made. We advise our companies who experience manufacturing challenges from prototyping to mass production. In order to achieve this, we provide strategic value to our portfolio companies by connecting them to cost-effective manufacturing partners throughout the plastic, PCBA, silicon/rubber and final assembly industries. Our partners are high-mix and low-volume suppliers who understand the challenges of start-ups. Outside of production, we assist companies with lower case costing, set-up and management. GOVERNANCE: Establishing a good corporate culture and necessary internal control will mitigate business losses from major risks and lay the foundations for a company to improve. In a later stage funding cycle, correct corporate governance and internal control are paramount before larger funds buy into the company’s vision and growth story. We have a complete understanding of control and our networks are comprised of global experts in financial knowledge and risk assurance who can work together with our companies. FUNDRAISING: We typically fund companies while they are still young, from their seed to their series A round. Given the heavy research and development nature of medical technology companies, they usually require additional funding in order to boost their business quickly. Post-investment, we will not only collaborate on budgets and milestone adjustments but will more importantly offer assistance with financial modeling and revenue projection. This ensures that companies gain a higher chance of future investment. Finally, we work with other larger funds all over the world who specialise in revenue growth in order to understand their needs when they select their investment targets. EXIT: We seek founders with longer-term goals and a desire to take their companies to global players. Given our evergreen nature and flexible exit strategy, we are well suited to the long operation cycle of healthcare companies. At the same time, we understand and respect that some founders have a shorter term goal of M&A to boost market shares, expand business services or leverage bigger players to scale the company. We are experienced in company buy-out considerations and offer our support to founders as long as the company fits within our investment mandate.

Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Our investment portfolio spans across agri-food, energy, resources, property and lifestyle. Tattarang is looking for talented individuals with experience in the health-tech field (including biotech, med-tech, life sciences, healthcare, and digital health).

Red Sea Ventures is a leading NY-based, pre-seed and seed stage venture firm investing in tech-enabled, user-centric consumer and B2B startups. In our first fund, we invested in category leading companies across sectors including Allbirds, Convoy, Nest, Eargo, Prose, Genies, Joor, and Sweetgreen. We are looking to partner with mission driven founders seeking to transform the economy and the lives of their teams and users. We are an entrepreneurial firm that values friendliness, humility, camaraderie, collaboration, determination, independence, and hustle with a commitment to performance. We are building RSV as a platform for community; bringing together our visionary founders, LPs, and relationships at large to support the companies we choose to partner with.

Our mission is simple: to accelerate the journey from high potential to highly valuable. Vocap PhilosophyCultivate collaborative and accretive partnerships: we are entrepreneurs investing in entrepreneurs. Build trust and make sure all parties’ interests are aligned as the business grows. Add value: we are here to help with our time, operational experience, and investor, banker, and industry networks. Invest in great people and implement efficient processes, as talent & time are the most finite constraints on a company. Have fun along the way: building a business should be both challenging and rewarding. Investment Focus Vocap partners with today’s disruptive technology companies to provide capital, operating experience, and critical relationships at the “classic” Series A stage. We focus on: Stage: Proven product-market fit $1-5 million revenue (SaaS or highly recurring) Strong & efficient growth (>30% YoY) Excellent unit economics Reasonable cash burn Sectors: Enterprise Productivity Software Healthcare IT FinTech Supply Chain & Industrial Software Media & Entertainment Software Structure: $2-6 million initial check Lead or partner Reserve capital for follow-on Target 2-7 year exit time frame Geography: Headquartered in North America Core focus on Eastern and Southern metros